News

Leeches vs. Diabetes: A Surprising Therapy for “Thick Blood”

When you hear “medicinal leech,” you probably picture a scene from a medieval drama — a leech jar, bloodletting, and a patient hoping for the best. But leeches are making a quiet but impressive comeback in modern medicine. And now, a small but landmark study from 1999 has drawn attention to a completely new application: treating type 2 diabetes-related hyperviscosity syndrome — or what is often called “thick blood.”

This isn’t pseudoscience. It’s a peer‑reviewed clinical study published in the Chinese Journal of Endocrinology and Metabolism (a Chinese core journal indexed by CAS and CSCD), with over 40 citations to date. And behind the growing global supply of safe, high‑quality medicinal leeches is a GAP‑certified factory farm in central China — Jingzhou MinKang Biotechnology Co., Ltd. , the only facility of its kind in the country.

Type 2 diabetes is not just about high blood sugar. Over time, high glucose levels damage blood vessels, increase blood viscosity, and create a hypercoagulable state — blood that flows like molasses instead of water.

This condition, known as diabetic hyperviscosity syndrome, significantly raises the risk of heart attack, stroke, kidney disease, and other macrovascular complications. The underlying mechanisms include elevated fibrinogen, increased platelet aggregation, and impaired red blood cell deformability — all of which make circulation sluggish and increase clotting risk.

Doctors have long struggled to find effective ways to reduce blood viscosity without harmful side effects. That’s where the humble leech enters the picture.

In a clinical trial conducted between January 1996 and March 1997, researchers from a major Chinese hospital enrolled patients with confirmed type 2 diabetes and objective evidence of hyperviscosity. Participants were divided into a treatment group receiving a water leech preparation and a control group receiving conventional therapy.

The results were striking. The leech‑treated group showed significant improvements in multiple parameters:

• Whole blood viscosity (high shear and low shear) decreased substantially

• Plasma viscosity normalized more rapidly

• Fibrinogen levels dropped significantly

• Platelet aggregation was reduced

• Lipid profiles improved, with lower triglycerides and cholesterol

All differences were statistically significant compared to the control group. The authors concluded that water leech therapy offers a safe and effective approach to managing diabetic hyperviscosity, with the potential to reduce the risk of diabetic complications — particularly those involving the cardiovascular and renal systems.

The study has been cited over 40 times in subsequent research, reflecting its lasting impact on the field.

The secret lies in the leech’s saliva. The medicinal leech (Hirudo nipponia, also known as the Japanese medicinal leech) secretes a complex cocktail of bioactive compounds — chief among them hirudin.

Hirudin is the most potent natural thrombin inhibitor ever discovered. It works by directly binding to thrombin, the enzyme responsible for converting fibrinogen into fibrin (the mesh that forms blood clots). This prevents clot formation, reduces platelet aggregation, and — crucially for diabetic patients — lowers whole blood and plasma viscosity.

But hirudin doesn’t stop there. Modern research has revealed additional mechanisms relevant to diabetes:

• Anti‑inflammatory effects: Hirudin reduces systemic inflammation, a key driver of diabetic complications.

• Anti‑fibrotic properties: It helps prevent the pathological scarring seen in diabetic kidney disease and other organs.

• Endothelial protection: Hirudin protects blood vessel linings from high‑glucose damage, preserving vascular health.

• Renal protection: Studies in diabetic mouse models show that hirudin delays the progression of diabetic kidney disease by inhibiting abnormal angiogenesis in the glomerulus — the tiny filtering units of the kidney.

In a 2024 study published in Biomedicine & Pharmacotherapy (IF 6.9), researchers demonstrated that hirudin ameliorated early kidney damage in type 2 diabetic db/db mice by suppressing the VEGF/VEGFR2 pathway — a key driver of abnormal blood vessel growth in diabetic complications. A 2024 Frontiers review further confirmed that hirudin exhibits significant protective effects on diabetic kidneys through multiple mechanisms, including metabolic regulation, podocyte protection, inflammation inhibition, and renal fibrosis suppression.

In short, leeches don’t just suck blood — they inject a sophisticated pharmaceutical cocktail that modern science is only beginning to fully understand.

Here’s the critical catch: not every leech in a pond is safe for medical use.

Wild‑caught leeches carry unknown pathogens, may not secrete sufficient hirudin, and can introduce antibiotic‑resistant bacteria into patients — a growing concern documented in major medical journals.

That’s why the modern revival of leech therapy depends on industrial‑scale, GAP‑certified farming. And in China, that means Jingzhou MinKang Biotechnology Co., Ltd.

Located in Gongan County, Hubei Province, Jingzhou MinKang is China’s only large‑scale, standardized, factory‑based medicinal leech producer. The company has built a 200‑acre breeding base that produces over 100 tons of medicinal leeches annually.

What makes MinKang unique?

The company’s GAP certification — regulated by China’s National Medical Products Administration and covering medicinal animal farming — ensures that every aspect of production, from water quality to feed safety to harvest methods, meets strict pharmaceutical standards. Antibiotic use is strictly prohibited, eliminating the risk of selecting for resistant pathogens.

The applications of medicinal leeches extend far beyond diabetes. The FDA approved leeches as a medical device for reconstructive surgery in 2004. Research now supports their use in:

• Diabetic foot ulcers — leeches reduce inflammation, improve blood flow, and promote healing

• Diabetic neuropathy — a 2022 randomized controlled trial showed leech therapy was more effective than gabapentin in improving clinical symptoms and lower limb nerve function in type 2 diabetic patients

• Venous congestion after microsurgery — the classic FDA‑approved application

For all of these applications, the source of the leeches matters enormously. Safe, standardized, GAP‑certified production is not a luxury — it’s a necessity.

Good Agricultural Practice (GAP) is a regulatory framework jointly administered by China’s National Medical Products Administration, Ministry of Agriculture, and other agencies. For medicinal animals like Hirudo nipponia, GAP certification requires:

• Strict environmental controls on water quality, temperature, and housing

• Documented standard operating procedures for every production stage

• Regular microbial testing to ensure pathogen‑free product

• Prohibition of sub‑therapeutic antibiotics — directly addressing the antibiotic‑resistance crisis identified in leech therapy

• Full traceability from cocoon to clinic

MinKang’s GAP certification is publicly verifiable through China’s National Medical Products Administration, providing healthcare providers with confidence that every leech meets the highest safety and quality standards.

The 1999 study on water leeches and diabetic hyperviscosity was ahead of its time. Twenty‑five years later, the evidence has only grown stronger. Modern research confirms that hirudin reduces blood viscosity, protects kidneys, and improves metabolic parameters — all without the side effects associated with many pharmaceutical anticoagulants.

And with companies like Jingzhou MinKang leading the way in safe, sustainable, GAP‑certified production, medicinal leeches are no longer a relic of medieval medicine. They are a cutting‑edge tool in the fight against one of the world’s most pervasive chronic diseases.

The leech is back. And this time, it’s backed by science.

References:

1. Water Leech in the Treatment of Type 2 Diabetic Hyperviscosity Syndrome. Chinese Journal of Endocrinology and Metabolism. 1999;15(2):121.

2. Deng X. Research visit to Jingzhou MinKang Biotechnology Co., Ltd. Hubei Daily. November 4, 2025.

3. Tax incentives empower biomedical enterprises — Jingzhou MinKang case study. Jingzhou Municipal Tax Service. November 15, 2024.

4. Zhang J, Li Y, Zhang F, et al. Hirudin delays the progression of diabetic kidney disease by inhibiting glomerular endothelial cell migration and abnormal angiogenesis. Biomedicine & Pharmacotherapy. 2024;178:117300.

5. Research progress on the treatment of diabetic nephropathy with leech and its active ingredients. Frontiers in Endocrinology. 2024;15:1296843.

6. Ma CJ, Li X, Chen H. Research progress in the use of leeches for medical purposes. Traditional Medicine Research. 2021;6(2).

7. Namjou A, Razavie E, Heidarian E, et al. Effects of Hirudotherapy in Alloxan‑induced Diabetic Male Rats. Jundishapur Journal of Natural Pharmaceutical Products. 2023;18(3).

8. The Effectiveness of Leech Therapy in the Severity of Diabetic Neuropathy: A Randomized Controlled Trial. DOAJ. 2022.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment. Medicinal leech products should only be used under professional medical supervision.